Core Viewpoint - Fuhong Hanlin (2696.HK) has seen a significant stock price increase, reaching a historical high of 82.75 HKD, with a market capitalization of 44.9 billion HKD, reflecting a year-to-date increase of 249% and a remarkable rebound of 444.41% from its low of 15.2 HKD on January 23 [1][3] Group 1: Stock Performance - The stock price of Fuhong Hanlin surged by 7.6% in the afternoon session, marking a new historical high [1] - The company's market capitalization reached 44.9 billion HKD, with a year-to-date increase of 249% [1] - Compared to its year-to-date low of 15.2 HKD, the stock has rebounded by 444.41% [1] Group 2: Research and Development - Fuhong Hanlin had 10 studies in the lung cancer field selected for presentation at the 2025 World Lung Cancer Conference (WCLC), including 4 oral presentations and 2 poster discussions, indicating the company's growing influence in the global academic arena [1] - The studies cover various first-line treatment areas for NSCLC and SCLC, showcasing the company's research capabilities [1] Group 3: Analyst Ratings - Citigroup has significantly raised Fuhong Hanlin's target price from 35 HKD to 95 HKD and upgraded its rating from "Neutral" to "Buy" [1] - The firm anticipates that the upcoming data on HLX43 at the WCLC will further demonstrate its potential in treating NSCLC [1] - Citigroup estimates that the risk-adjusted peak sales for HLX43 could reach approximately 2.3 billion USD, with additional upside potential if more data is obtained for NSCLC and other indications [1]
港股异动丨复宏汉霖涨超7% 股价创历史新高 较年内低点已反弹超4倍！